+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Years +
All Genders
ID07783425

Evaluating Tilrekimig Compared to Dupilumab and Placebo for Moderate-to-Severe Atopic Dermatitis in Participants Aged 12 and Older in a Randomized, Controlled Study

Led by Pfizer · Updated on 2026-10-22

1375

Participants Needed

32

Research Sites

40 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how well tilrekimig works, its safety, and effects on the body in adults and adolescents aged 12 years and older with moderate to severe atopic dermatitis, a skin condition causing dryness, itching, and redness. The study includes participants who have had atopic dermatitis for at least one year and have not responded well to topical medicines. The trial is a Phase 3 randomized, double-blind study comparing tilrekimig, dupilumab, and placebo. Participants will receive subcutaneous injections during a 24-week initial treatment period, randomized in a 221 ratio to tilrekimig, dupilumab, or placebo. This is followed by a 28-week maintenance period where study drugs continue until the last dose at week 48. Some participants may join a long-term extension study at week 52 to further evaluate treatment effects and safety, while others will enter a 12-week safety follow-up period after their last dose. During the trial, participants will have regular visits for assessments including skin evaluations using the Eczema Area and Severity Index EASI and Investigator Global Assessment scales. Other measures include patient-reported skin itch severity and quality of life questionnaires. Safety is monitored through adverse event tracking, vital signs, and laboratory tests, with follow-up continuing for at least 16 weeks after the last dose. The total study participation lasts up to 64 weeks, including treatment and follow-up periods.

CONDITIONS

Brief Title

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

Research Team

P

Pfizer CT.gov Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here